SAN
DIEGO, Aug. 30, 2023 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused
on developing products to treat cancer and life threatening
infectious diseases, today announced that Steven LaRosa, M.D., Chief Medical Officer, and
James Frakes, Chief Financial
Officer, will present a company overview on Tuesday, September 12 at 4:30 PM EST, during the H.C. Wainwright
25th Annual Global Investment Conference taking place
September 11-13, 2023, in
New York City.
Management will also host in-person, one-on-one meetings during
the event. Institutional investors who are registered for the
conference can log into www.hcwevents.com to request a meeting with
the company or may reach out to Susan
Noonan at susan@sanoonan.com.
A live webcast of the presentation will be available on the
Aethlon Medical website at:
https://www.aethlonmedical.com/news-media/events. An archived
replay will be available on the company's website for a period of
90 days after the conference.
About Aethlon and the Hemopurifier®
Aethlon
Medical is a medical therapeutic company focused on developing the
Hemopurifier, a clinical stage immunotherapeutic device which is
designed to combat cancer and life-threatening viral infections. In
human studies, the Hemopurifier has demonstrated the removal of
life-threatening viruses and harmful exosomes from blood utilizing
its proprietary lectin-based technology. This action has potential
applications in cancer, where exosomes may promote immune
suppression and metastasis, and in life-threatening infectious
diseases. The Hemopurifier is a U.S. Food and Drug
Administration (FDA) designated Breakthrough Device indicated for
the treatment of individuals with advanced or metastatic cancer who
are either unresponsive to or intolerant of standard of care
therapy, and with cancer types in which exosomes have been shown to
participate in the development or severity of the disease. The
Hemopurifier also holds an FDA Breakthrough Device designation and
an open Investigational Device Exemption (IDE) application related
to the treatment of life-threatening viruses that are not addressed
with approved therapies.
Additional information can be found at
www.AethlonMedical.com.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301913304.html
SOURCE Aethlon Medical, Inc.